iOrganBio Launches AI-Powered Cell Manufacturing Platform with $2M Funding
ByAinvest
Wednesday, Oct 29, 2025 9:29 am ET1min read
iOrganBio emerges from stealth with $2 million funding and launches CellForge, an AI-powered cell manufacturing platform. The platform combines AI-driven prediction with high-throughput experimental control to engineer cells and organoids for drug discovery, manufacturing, and cell therapies. CellForge uses closed-loop control of 3D culture environments to optimize culture conditions during human pluripotent stem cell differentiation, enabling predictable and reproducible outcomes. The platform can be applied in various contexts, including disease modeling, regenerative medicine, and drug development.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet